Whereas, MS-HRM analysis of IL12b promoter revealed the mean percentage methylation of −1.474 ± 0.4741 (p < 0.05) in CAD patients as compared to 0.5325 ± 0.7064 in control subjects (Fig. 18). Here, IL12B is linked to coronary artery disorder.